(2009) 1... / 1 ( ) / 1 ( ) / 1 ( ), 2 ( )
|
|
|
- さや ちゅうか
- 7 years ago
- Views:
Transcription
1
2 (2009) 1... / 1 ( ) / 1 ( ) / 1 ( ), 2 ( ) / 1 ( ) / 1 ( ) / 3 ( ) / 1 ( ) / 2 ( ) / 3 ( ) / 1 ( ) / 1 ( ) / 1 ( ) / 2 ( ) / 2 ( ) / 2 ( ) / 2 ( ) / 3 ( ) / 2 ( ) / 2 ( ) / 3 ( ) / 1 ( ) / 1 ( ) / 2 ( ) / 1 ( ) / 1 ( ) / 2 ( ) / 3 ( ) / 4 ( ) / 3 ( ) / 1 ( ) / 3 ( ) / 3 ( ) / 2 ( ) / 2 ( ) / 3 ( ) / 1 ( ) / 2 ( ) / 2 ( ) / 3 ( ) / 3 ( ) / 3 ( ) / 3 ( ) / 4 ( ) / 4 ( ) / 3 ( ) / 3 ( ) / 1 ( ) / 2 ( ) / 3 ( ) / 1 ( ) / 3 ( ) / 2 ( ) / 3 ( ) / 4 ( ) / 4 ( ) / 4 ( ) / 2 ( ) / 3 ( ) / 3 ( )
3 (2009)... / 3 ( ) / 4 ( ) / 4 ( ) / 2 ( ) / 4 ( ) ()... / 3 ( ) / 3 ( ) / 4 ( ) / 3 ( ) / 4 ( ) / 4 ( ) / 4 ( ) / 4 ( ) I( )... / 1, 2, 3, 4, 5, / 2 ( ) / 2 ( ) / 2 ( ) / 2 ( ) / 2 ( ) / 2 ( ) / 2 ( ) / 2 ( ) / 2 ( ) / 2 ( ) / 2 ( ) / 3 ( ) / 2 ( ) / 1 ( ), 2 ( ) / 4 ( ) / 5 ( ) / 5 ( )
4 (2009) A-(1) 1 Introduction to Pharmaceutical Sciences 1 1 ( ) 1 ( ) / / 1. 1) 2. 1) QOL 3. 1) ( ) 1. 1 ( ) 2. 2 ( ) 3. 3 ( ) 4. 4 ( ) 5. 5 ( ) 6. 6 ( ) 7. 1 ( ) 8. 1 ( ) 9. 2 ( ) ( ) ( ) ( ) ( ) ( ) 15. ( ) (): ([email protected]) Mail ( B 3, , [email protected] -u.ac.jp) Mail 4
5 (2009) A-(2),(3) 2 Introduction to Pharmaceutical Sciences 2 1 ( ) 1 ( ) / / / 1. 1) a. b. c. 2) 3) 4) 5) 6) 7) 8) 2. 1) 2) 3) 4) 5) 6) 7)
6 (2009) ( , Mail (, , Mail ( , Mail 6
7 (2009) B(1) 3 Guide to Pharmacy 3 1 ( ) 1 ( ), 2 ( ) ( 2 ) () 1. 1) 1. ( ) 2) 3) 4) 5) 2. 1) 2) 3. 1) 4. 1) 2) 3) 5. 1) 2) ) 2) (, , [email protected]) Mail ( 2, , [email protected]) Mail ( : 5 7 ) ( , [email protected]) Mail ( : ) ([email protected]) Mail ( , [email protected]) Mail ( 6, , [email protected]) Mail ( : ) ( 4F, , [email protected] shima-u.ac.jp) Mail ( , [email protected]) Mail ( , [email protected]) Mail (, , [email protected]) Mail ( : 8:30 17:30) ( , [email protected]) Mail (, , [email protected]) Mail ( : (9:00-16:00)) ( , [email protected]) Mail ([email protected]) Mail
8 (2009) C1(1) 1 Physical Chemistry ) 2) (1 ) 3) 4) 5) ( ) 6) 2. 1) () 2) van der Waals 1 ( ) 1 ( ) / 3) 4) 5) 1. ( ) 2. ( ) 3. Schrodinger (1) ( ) 4. Schrodinger (2) ( ) 5. (1) ( ) 6. (2) ( ) 7. ( ) 8. Pauli ( ) 9. ( ) 10. ( ) 11. ( ) 12. ( ) 13. Huckel ( ) 14. (1) ( ) 15. (2) ( ) () ( 4 ) (E )[email protected]( ) ( : 9:00 12:00 13:00 17:30( )) 8
9 (2009) C1(2), C2(3) 2 Physical Chemistry 2 1 ( ) 1 ( ) / 1. ( ) 1) 2. 1) 2) 3) 4) 5) ( ) 6) 7) 8) 3. 1) 2) 3) 4) 5) 6) 7) 8) ) (Clausius-Clapeyron ) 2) 3) ( ) 5. 1) 2) (1) 5. (2) 6. (1) 7. (2) (1) 11. (2) ( ) (, , [email protected]) Mail ( : 8:30 12:00 13:00 17:30) [email protected] 2 ( )
10 (2009) C1(3) (4) 3 Physical Chemistry 3 2 (1.0) 1 (0.5) 1. 1) 2) ( ) 2. 1) 2) 3) 4) 5) 6) (Debye-Hückel ) 3. 1) 2) 3) 4) Nernst 5) 4. 1) (1) 3. (2) (1) 7. (2) 8. (1) 9. (2) 10. (1) 11. (2) 12. (1) 13. (2) 14. (1) 15. (2) ( ) 3 ( ) / ( ) (, , [email protected]) Mail ( : 8:30 12:00 13:00 17:30) [email protected] 3 ( ) 10
11 (2009) C1(3), C2(1) (2) 1 Analytical Chemistry 1 1) ( ) 2) ( ) 3 (0.5)(0.5) (0.5) 1. 1) 2) SI() 3) 4) 2. 1) 2) ph ( ) 3) 4) (Mohr Fajans Volhard ) 5) ( ) 6. 2(pH) ( ) ( ) 1 ( ) / ( ) (, , [email protected]) Mail ( : 8:30 12:00 13:00 17:30) [email protected] 1 ( ) 11
12 (2009) C1(1), C2(2) (3), C3(1) 2 Analytical Chemistry ) 2. 1) () 2) Lambert - Beer 3) 3. 1) ( ) 2) 3) 4. ( ) 1) 2) 3) ( ) 5. 1) 1 ( ) 2 ( ) / 2) ORD / CD 3) ORD / CD 1. ( ) 2. ( ) 3. (1) ( ) 4. (2) ( ) 5. (3) ( ) 6. (1) ( ) 7. (2) ( ) 8. (3) ( ) 9. ( ) (1) ( ) 10. ( ) (2) ( ) 11. (1) ( ) 12. (2) ( ) 13. (3) ( ) 14. (4) ( ) () () ( 4 ) (E )[email protected]( ) ( : 9:00 12:00 13:00 17:30( )) 12
13 (2009) C2(1) (2) (3) 3 Analytical Chemistry ) 2) 3) 4) 2. 1) 2) 3. 1) 2) 4. 1) 2) 5. 1) 1. 1) 2. 2) 3. 1) 4. 2) 5. 3) 6. 1) 7. 2) ( ) 8. 3) 9. 4) 10. 5) 11. 1) 12. 2) 13. 3) ( ) 3 ( ) / :( 4) ( : 12:00-17:30 E ) 13
14 (2009) C-4-(1) 1 Basic Organic Chemistry C4 (1) (2) (3) (4) () ( ) ( ) 1 ( ) / 15. Fischer Newman () Saytzev Hofmann Markovnikov
15 (2009) ( 4 ) ( 6, , [email protected]) Mail ( : ) () ( 6 ) ( ) (E )[email protected] 15
16 (2009) C-4-(2) 2 Basic Organic Chemistry II 1 ( ) 1 ( ) / ( ) ( ) Base 1. 1) 2. 1) 2) 3) 4) 1. (1) 2. (2) 3. (3) 4. (4) 5. (1) 6. (2) 7. (1) 8. (2) 9. (1) 10. (2) 11. (3) 12. (4) 13. (1) 14. (2) () 6( ) (E ) [email protected]( ) ) ( :
17 (2009) C-4-(3) 3 Basic Organic Chemistry 3?? ( ) () 3 1 (1.0) 2 (1.0) 1 (1.0) 2 (1.0) () (SN1 SN2 ) 3. (Saytzev ) ( ) 1 ( ) / SN2 ( 6 ) 2. SN2 ( ) 3. SN2 4. SN1 ( 7 ) 5. SN1 / ( ) 6. Hammond 7. SN1 8. ( 9 ) 9. E1 ( 7 ) 10. E1 11. Saytzev 12. E2 ( 7 ) 13. E2 14. () 15. ( 8 ) 16. : I II III ()( 6) (E )[email protected],jp ) ( : 17
18 (2009) C4-(4) 4 Organic Chemistry 4 1 ( ) 2 ( ) / (NMR) (IR) H-NMR 3. H-NMR 1 4. H-NMR 2 5. C-NMR 6. C-NMR 7. IR 8. UV 9. MASS 10. X 11. CD ( ) 18 () 3F (E )[email protected]
19 (2009) C-5-(1) 1 Applied Organic Chemistry 1 1 ( ) 2 ( ) / 1 (1.0) 2 (1.0) 3 (1.0) 2 (0.5) ( ) Claisen 10. β- 11. α- 12. α,β- 13. / ( ) WEB ( , [email protected]) Mail ( : )
20 (2009) C-5-(2) 2 Applied Organic Chemistry ) 2) 2. 1) ) () 5. -3( ) ( ) ( ) ( ) 2 ( ) / ()(4 ) (E )[email protected] ( : 12 :00 13 :00) 20
21 (2009) C-6-(1) Bio-organic Chemistry 1 ( ) 2 ( ) /? 1. 1) 2) 3) 4) 2. 1) 3. 1) 2) 1. (1) 2. (2) 3. (1) (2) 5. (3) 6. (1) 7. (2) 8. (3) 9. (4) 10. (1) 11. (2) 12. (3) 13. (1) 14. (2) 15. Chemical Biology () 6 ( ) (E )[email protected]( ) ) ( :
22 (2009) C-6-(2) Medicinal Organic Chemistry ( ) C6 (2) 1. ( ) ( ) 3 ( ) / DNA β : II ( 6, , [email protected]) Mail ( : ) () ( 6 ) ( ) (E )[email protected] 22
23 (2009) C-7-(1) 1 Natural Medicines 1 1 ( ) 2 ( ) / 1. 1) 2) 2. 1) 2) 3) 3. 1) 2) ) ) 2) (1) 4. (2) (1) / (2) / (3) / ( ) ()( 5 ) (E )[email protected] 12 :00 13 :00) ( :
24 (2009) C-7(2) 2 Natural Medicines 2 1 ( ) 2 ( ) / / () () 1. 1) 2) 3) 2. 1) 2) 3. 1) 2) 3) (1) 4. (2) (1) / (1) 7. (2) / (2) 8. (3) / (3) 9. (4) / 10. (5) / 11. (6) / 12. (7) / 13. / 14. / 15. / 16. ( ) ()( 5 ) (E )[email protected] [email protected] ( : 12 :00 13 :00) 24
25 (2009) C-7-(3) 3 Natural Medicines 3 1 ( ) 3 ( ) / ) 2) 3) 4) 5) 6) 7) 2. 1) 2) L III ()( 5 ) (E )[email protected] 12 :00 13 :00) ( :
26 (2009) C8 (2) 1 Biopharmacy ) 2) 2. 1) 2) 3) 3. 1) ( ) 4. 1) 2) 3) 4) 5. 1) 2) ( ) 1 ( ) / ( 5 ) ( , [email protected]) Mail ( : ) 26
27 (2009) C8-(1) 2 Biopharmacy ) 2. 1) 3. 1) 4. 1) 5. 1) 6. 1) 7. 1) 8. 1) 1 ( ) 1 ( ) / 9. 1),, 1. 1 : ( ), ( ) () (4)TEL: (E )[email protected] ( : 12:00-13:00) 27
28 (2009) C8(4) 3 Biopharmacy 3 ( 2 ) () 1. 1) 2) 2. 1) 2) 3) 4) 5) 6) () 3. 1) 4. 1) 2) 3) 5. 1) 1 ( ) 2 ( ) 1. 1) (30 ) 2) (10 ) 3) (10 )
29 (2009) C-9-(1)(2) 1 Biochemistry 1 1 ( ) 1 ( ) / DNA ( ) ) 2) 2. 1) 2) 3. 1) 4. 1) DNA RNA 2) () 5. 1) 2) DNA RNA 3) 4) 5) ( ) 6) RNA ) DNA RNA 2) 3) RNA 4) RNA 5) 7. 1) DNA 2) ( ) 3) DNA 8. 1) (SNPs) DNA RNA 4. DNA 5. DNA () : : 8,190 ( 7,800 )
30 (2009) 4. ) ( : 30
31 (2009) C9 (3) 2 Biochemistry 2 1 ( ) 1 ( ) / 1. 1) 2) 3) 2. 1) 2) 3) 4) 5) 3. 1) ( ) 2) 3) 4) 5) 4. 1) 2) 1. (Edman ) 2., α β β, 31 3.,, 4. (1) 5. (2) ,, ( ) 9. () 10. (, Km, Vmax, ) 11. ( ) 12. () 13. (, Allosetric Enzyme) ( ) ()3 (E ) [email protected] ) ( :
32 (2009) C-9-(4) 3 Biochemistry 3 1 ( ) 2 ( ) / ) 2. ATP 1) ATP 2) 3) 4) (. 5) β- 6) CoA 7) 8) ATP 9) 10) 3. 1) 2) 3) ( ) 4) 5) 6) 32 7) 8) 9) 4. 1) 2) (1) 6. (2) 7. (3) (1) 10. (2) 11. (3) 12. (1) 13. (2) ( : ) () ( 3 ) (E )[email protected] ) ( :
33 (2009) C9(5) 4 Biochemistry 4 1 ( ) 3 ( ) / 1. 1) 2) 3) 4) 2. 1) 2) 3) ( ) 4) ( ) 5) () 6) 3. 1) 2) 33 3) 4) 4. 1) 2) 3) 5. 1) 2) G 3) 4) ( ) 1., , 5. 6., NO, G - 9. G G - C 11. G TGF 13. Ras-MAPK 14. PI3-Kinase (AKT)
34 (2009) 5 () : ( ) 5 : () ()( 3 ) (E )[email protected] ) ( : 34
35 (2009) C13-(3) Physiology 1 ( ) 4 ( ) / ( ) ( ) ( ) 2. I II 4. I 5. II 6. I 7. II 8. I 9. II 10. I 11. II 12. I 13. II 14. I 15. II ( ) (2,400 + )() (7,600 + ) () (3 ) (E )[email protected] ( : ) 21
36 (2009) C9(2),(6) Gene Technology 1 ( ) 3 ( ) / DNA RNA DNA 1. 1) ( ) 2) 3) 4) ( ) 2. 1) DNA RNA 2) DNA RNA 3) 4) RNA 3. 1) 2) cdna DNA ) RNA 1 ( 5 )H. Lodish, A. Berk, C.A. Kaiser, M.Krieger, M.P. Scott, P. Matsudaira, S. L. Zipursky, J. Darnell, (2005) () () ( 2 ) (E )[email protected] ( : E)
37 (2009) C-10-(1) 1 Cell Biology 1 1 ( ) 1 ( ) / 1. 1) 2) - 3) 4) ( ) 5) 6) 2. 1) 2) 3) 4) 3. 1) 2) MHC 3) T 4) T ( ) 5) () 9. (1) BCR TCR 10. (2) TCR MHC ( ) 4, ( )3, [email protected] ( : )
38 (2009) C10(2) 2 Cell Biology 2 1 ( ) 3 ( ) / (1) 3. (2) [email protected] 38
39 (2009) C10(3) 3 Cell Biology 3 ( 2 ) () 1. 1) DNA (EB B19 B ) 2) RNA ( A C ) 3) (HIV HTLV) 4) () 5) ( ) 6) ( ) 7) ( ) 1 ( ) 3 ( ) 8) () 9) ( ) 10) 11) ( ) 12) 13) 2. 1) 1. 1) (30 ) 2) (10 ) 3) (10 )
40 (2009) C-11- (2),(3) 1 Pharmaceutical Health Sciences 1 1 ( ) 2 ( ) / / ( ) 1. 1) () 2) 2. 1) 2) 3) 3. 1) 2) (WHO) 4. 1) 2) 5. 1) 2) 40 3) 4) 6. 1) 2). 3) 4) 7. 1) 2) 8. 1) 2) () 3) () 4) 5) () ( )
41 (2009) ( ) ()( 3 ) (E )[email protected] ) ( : 41
42 (2009) C-11- (1) 2 Pharmaceutical Health Sciences 2 1 ( ) 2 ( ) / ( ) ( ) ) 2) 3) 2. 1) 2) (Ames ) 3) 3. 1) 2) PCB 3) 4) (NOAEL) 42 5) (1 ) 6) () 7) () 4. 1) 5. 1) 2) 3) 4) () 5) 6) 7) 8) 9) 6. 1) 2) 3) 4) ( ) (1) 5. (2) (1)
43 (2009) 8. (2) (1) 11. (2) (1) 14. (2) ( ) ()( 3 ) (E )[email protected] ) ( : 43
44 (2009) C-12-(1) (2) Environmental Pharmacy 1 ( ) 3 ( ) / : 1. 1) 2) 3) 4) 5) 6) 2. 1) 2) 3) 4) 5) 6) 7) 3. 1) 2) 44 3) 4) () 4. 1) 2) 3) 4) 5. 1) 2) 3) 6. 1) 2) 3) 4) PRTR 7. 1) 2) 3) 4)
45 (2009) PRTR () ( 3 ) (E )[email protected] ) ( : 45
46 (2009) C13-(1) 1 Basic Clinical Pharmacy 1 1 ( ) 1 ( ) / 1. 1) () 2) ( ) 3) ( ) 4) 5) 6) 7) 2. 1) 2) 3) 4) 5) 6) 7) ) ( ) 2) 3) 4. C13-(1) 1. / 2. / 3. / 4. / 5. / 6. / 7. / 8. / 9. / 10. / / 11. / 12. / 13. / 14. / 15. /
47 (2009) ( 4 ) 1( ) [email protected] : ) ( 47
48 (2009) C8-(3), C13-(2) 2 Basic Clinical Pharmacy 2 1 ( ) 2 ( ) / ( ) 1. 1) 2. 1) 2) 3) ( ) (2,400 + ) ( ) (7,600 + ) ()( 3 ) (E )[email protected] ( : )
49 (2009) C8-(3), C13-(2), (3) 3 Basic Clinical Pharmacy 3 2 ( ) 1. 1) ( ) 2 ( ) / 5 ( ) (2,400 + ) ( ) (7,600 + ) () (3 ) (E )[email protected] ( : ) 49
50 (2009) C13-(4) 4 Basic Clinical Pharmacy 4 1 ( ) 3 ( ) / 1. 1) 2) 3) ( ) 4) 5) 6) 2. 1) 2) - 3) 4) ( ) 5) () 6) 7) 3. 1) 2) 3) 4) P ) 6) 7) (SNPs ) 8) 9) 4. 1) 2) 3) 4) 5) 6) 7) 5. 1) 2) 1. I [email protected] : ) (
51 (2009) C13-(5) 5 Basic Clinical Pharmacy 5 TDM 1 (1.0) 4 (0.5) 1. 1) 2) 3) 1-4) 2-5) 6) 7) 8) 9) 10) 11) 12) 2. TDM (Therapeutic Drug Monitoring) 1) (TDM) 2) TDM 3) 4) 5) 1 ( ) 3 ( ) / 1. (1 ) / 2. AUC (1 ) / (AUC) (1 ) / (1 ) / 1-0 ( ) 5. 1 (1 ) / 1-1 ( ) 6. (2 ) / 1-7. (2 ) / (2 ) / () 9. (2 ) / 10. TDM(2 ) / TDM ( 4 ) 51
52 (2009) : ) ( 52
53 (2009) C14-(1)(2) 1 Pharmacotherapy 1 1 ( ) 3 ( ) / Practical pharmacy 1. 1) 2) 2. 1) 2) 3. 1) 2) 4. 1) 2) ) 2) 1. (1) 2. (2) II ()2 (E )[email protected] ( : )
54 (2009) C-14-(3) 2 Pharmacotherapy 2 aaa 1. 1) ( ) 2) 3) 4) 5) 6) 1 ( ) 3 ( ) / 2. 1) 2) 3) 4) 3. 1) 2) 3) 4. 1) 2) () 3) () 5. 1) 2) 3) 6. 1) 54
55 (2009) 2) 3) 4) 5) 6) 1. () 2. () 3. () 4. () 5. ( ) ( ) 8. ( ) 9. ( 1) 10. ( 2) 11. () 12. ( ) 13. ( ) 14. ( - ) 15. ( ) II (1) ()2 (E )[email protected] ( : E ) 55
56 (2009) C14-(4) 3 Pharmacotherapy 3 1 ( ) 4 ( ) / 1. (SBO58,59) 2. ( ) (SBO 60,61) 3. (SBO62, 63) 4. (SBO64) 5. (1) (SBO65, 66)) 6. (2) (SBO67, 68) 7. (1) (SBO69,70) 8. (2) (SBO70-72) 9. (1) (SBO73,74) 10. (2) (SBO75,76) 11. (SBO77,78) 12. (SBO79) 13. (SBO80) (SBO82, 83) 15. (SBO84) 16. 3,, II. (1), () ( )5 (E )[email protected] ( : ) 21
57 (2009) C14(5) 4 Pharmacotherapy 4 1 ( ) 4 ( ) / ( , [email protected]) Mail 21
58 (2009) C-15-(1),(2) 1 Drug Informatics 1 () () 1. 1) 2) 3) 2. 1) 2) 3) 4) 3. 1) 4. EBM(Evidence-Based Medicine) 1 ( ) 3 ( ) / 1) EBM EBM 5. 1) (POS) EBM ICT : ( , [email protected]) Mail 58
59 (2009) C15-(3) 2 Drug Informatics 2 1 ( ) 3 ( ) / Practical pharmacy 1. 1) 2) 3) 2. 1) 2) 3. 1) 2) ( ) 4. 1) 2) 5. 1) 2) 3) PK/PD (1) 3. PK/PD (2) 4. PK/PD (1) 5. PK/PD (2) 6. PK/PD 7. PK/PD 8. PK/PD 9. PK/PD 10. PK/PD (1) 11. PK/PD (2) 12. TDM (1) 13. TDM 2) 14. TDM III ()2 (E )[email protected] ( : )
60 (2009) C-16-(1),(2) 1 Physical Pharmacy 1 1 ( ) 1 ( ) / 1 2 () 1 (0.5) 2 (0.5) ) 60 2) 3) 4) 2. 1) 2) 3) 4) 5) 3. 1) 2) 3) 4) 5) 6) 7) X 4. 1) 2) 3) 5. 1) 6. 1)
61 (2009) ( ) ( , [email protected]) Mail 61
62 (2009) C-1-(4), C-16-(3) 2 Physical Pharmacy 2 1 ( ) 2 ( ) / DDS (Drug Delivery System DDS, ), DDS 1 (0.5) 1 (0.5) DDS DDS 1) 2) DDS 3. 1) ( ) 2) 3) 4) 5) 6) 4. 1) 2) 5. 1) DDS 1) () 9. DDS DDS 15. (DDS) 16. ( ) () ( ) ( ) () ( 5 ) (E )[email protected] 12:00-13:00) ( :
63 (2009) B(1), C2(2) Japanese Pharmacopoeia 1 ( ) 3 ( ) / / 1. 1) 2. 1) 2) 3) 4) ( ) 8. ( 1) 9. ( 2) 10. () 11. ( 1) 12. ( 2) 13. ( 1) 14. ( 2) , ( , [email protected]) Mail ( : 8:30 12:00 13:00 17:30) (, , [email protected]) Mail ( : 8:30 12:00 13:00 17:30) 63
64 (2009) C-17-(1), (2) 1 Drug Development 1 1 ( ) 1 ( ) / () (3F) (E )[email protected] ( : )
65 (2009) C-17-(3), (4) 2 Drug Development 2 1 ( ) 3 ( ) / 1. 1) 2. 1) 3. 1) 1. (1) 2. (2) 3. (1) 4. (2) 5. (1) 6. (2) 7. (1) 8. (2) 9. (3) 10. (4) 11. (5) 12. (6) 13. (7) 14. (1) 15. (2) () 6 ( ) (E )[email protected]( ) ( : )
66 (2009) C-17-(5) 3 Drug Development 3 1 ( ) 2 ( ) / / (CRC) ( GCP ) 1. 1) 2) 3) 4) () ( ) ( ) 5) ( ) 2. 1) ( I II III ) 2) ( ) 3. 1) (t- Mann-Whitney U ) χ2 (Dunnett Tukey ) 2) ( 66
67 (2009) ) () (Kaplan-Meier ) 1. / 2. / 3. / 4. / 5. / 6. / 7. / 8. / 9. / 10. / 11. / 12. / 13. /, 14. / 15. () () ( : E ) ( : E ) 67
68 (2009) C 18-(1),(2) 1 Social Pharmacy 1 1 ( ) 3 ( ) ) 2) 2. 1) 2) 3) 4) 5) 6) 7) 8) 3. 1) 68 2) 3) 4) 4. 1) ( ) 2) OTC 1. ( ) 4,700 ( ) : ( 5671) : E : k [email protected]
69 (2009) C-18-(3) 2 Social Pharmacy 2 ( ), OTC 1. 1) 2) 3) 2. 1) 3. 1) 4. OTC 1) (OTC ) 2) (1) 3. (2) (1) 8. (2) (OTC )(1) 11. (OTC )(2) ( ) 4 ( ) / ( , [email protected]) Mail ( : ) 21 69
70 (2009) 1 Advanced Clinical Pharmacy 1 1 ( ) 4 ( ) / / / 1. 1) 2) 3) 4) 2. 1) PK/PD 2) 3) 3. 1) 2) 3) 4) 5) 4. 1) IT 2) 3) 4) PK/PD 6. PK/PD 7. PK/PD 8. PK (, , [email protected]) Mail ( , [email protected]) Mail ( , [email protected]) Mail 21 70
71 (2009) 2 Advanced Clinical Pharmacy 2 1 ( ) 4 ( ) / / / / 1. ( ) 1) 2) 2. ( ) 1) 2) 3) 3. () 1) 2) 4. DDS ( ) 1) DDS 2) DDS 3) DDS DDS 7. DDS 8. DDS ( : ) 2 ( : ) 3 ( : ) 4 ( : ) 21
72 (2009) 1 English for Pharmaceutical Sciences 1 1 ( ) 2 ( ) 1. 1) 2) 2. 1) 2) 3. 1) 2) 1. (, , [email protected]) Mail ( 2, , [email protected]) Mail ( : 5 7 ) ( , [email protected]) Mail ( : ) ([email protected]) Mail ( , [email protected]) Mail ( , [email protected]) Mail ( 4F, , [email protected] shima-u.ac.jp) Mail 72 ( , [email protected]) Mail ( , [email protected]) Mail (, , [email protected]) Mail ( : 8:30 17:30) ( , [email protected]) Mail (, , [email protected]) Mail ( : (9:00-16:00)) ( , [email protected]) Mail ([email protected]) Mail
73 (2009) 2 English for Pharmaceutical Sciences ) 2) 2. 1) 2) 3. 1) 2) (, , [email protected]) Mail ( 2, , [email protected]) Mail ( : 5 7 ) ( , [email protected]) Mail ( : ) ([email protected]) Mail ( , [email protected]) Mail ( 6, , [email protected]) Mail ( : ) 1 ( ) 3 ( ) ( 4F, , [email protected] shima-u.ac.jp) Mail ( , [email protected]) Mail ( , [email protected]) Mail (, , [email protected]) Mail ( : 8:30 17:30) ( , [email protected]) Mail (, , [email protected]) Mail ( : (9:00-16:00)) ( , [email protected]) Mail ([email protected]) Mail 73
74 (2009) Pathology 1 ( ) 3 ( ) / () () 7. ( ) 8. () 9. ( ) 10. ( ) 11. ( ) 12. () 13. ( ) ( ) 14. ( ) 15. () ( 4 ) ( , [email protected]) Mail ( : ) 74
75 (2009) Pathology () 1. 1) 2) 3) 4) 5) 2. 1) 2) 3) 4) 5) 6) 7) 8) 1. 1 ( ) 3 ( ) / ; ( ) () ()() ()1 (E )[email protected] ) ( : 75
76 (2009) Integrative Medicine 1 ( ) 4 ( ) / / OTC OTC OTC ()5 (E )[email protected] [email protected] a-u.ac.jp ( : ) 21 76
77 (2009) Neuroscience 1 ( ) 4 ( ) / ) 2) 3) 4) 2. 1) () 2) 3) 4) 5) 6) 3. 1) 2) 3) 4) 4. 1) 2) ) 2) / , 13. (1) 14. (2) 15. (3) () ( 3 ) (E )[email protected] ) 21 ( :
78 (2009) C3(2) Structural Biology 1 ( ) 2 ( ) / 1. ( ) [email protected] 78
79 (2009) Drug Safety Study 1. : 2. : 3. : 4. : 5. : ( ) 4 ( ) / : & ( - D ) 1 4( ) () () () 272 ( ) ( ) ( , [email protected]) Mail 21 79
80 (2009) C1(1) (2) (4) C3(2) C4(1) (2) C6(1) (2) () Pharmacoinformatics 1 ( ) 3 ( ) / - () ) 2) 3) 4) 2. 1) ( ) 2) 3. 1) Hammett 2) 3) 4. 1) (1) 3. - (2) (1) 6. (2) 7. (3) 8. (1) 9. (2) ( ) 10. (1) 11. (2) 12. (3) 13. (4) ( ) 14. (5) ( )() ( 4 ) (E )[email protected]( ) ( : 9:00 12:00 13:00 17:30)
81 (2009) C-4-(1) Inorganic Chemistry 1 ( ) 3 ( ) / 1 (0.5) ( ) 1. 1) 2) 3) 4) 2. 1) 2) 3) 4) 3. 1) 2) 3) 4) 5) 6) 7) ) 2) 3) 4) 5) 5. 1) 2) 3) 4) 5) () 6) 7)
82 (2009) ( ) ( ) () ( 5 ) (E )[email protected] 12:00-13:00) ( : 82
83 (2009) C18-(2) Pharmacoeconomics 1 ( ) 4 ( ) / 1 EBM(Evidence-Based Medicine) 1. 1) 2. 1) 2) 3) 3. 1) 2) 4. 1) 2) 5. 1) 2) 6. EBM (Evidence-Based Medicine) 1) EBM 83 2) QOL QOL : ( ) () (E )[email protected] ( : 9 17 ) 21
84 (2009) C-6-(2) 1 Medicinal Chemistry 1 1 ( ) 3 ( ) / ( ) ( ) () ( ) 1 (1.0) 2 (1.0) 3 (1.0) 2 (1.0)(1.0) 1 (1.0) ( ) / 2. / 1 3. / 2 4. / 3 5. / 6. HMG-CoA / 1 7. HMG-CoA / 2 8. H2 / 1 9. H2 / ( ) / ( ) / / 13. / 14. / / : :; ( , [email protected]) Mail ( : )
85 (2009) Clinical Psychology 1 ( ) 4 ( ) /(0.5) / (0.5) /(0.5) () (E )[email protected] ( : ) 21
86 (2009) 1 Internal Medicine 1 1 ( ) 4 ( ) / / / / / / / 1. 1) 2) 3) 4) 5) 2. 1) 2) 3) 4) 3. 1) 2) 3) 4) 5) 1. ( ) 2. ( ) 3. ( ) 4. ( ) ( ) 6. ( ) 7. ( ) 8. ( ) 9. ( ) 10. () 11. () 12. () 13. ( ) 14. ( ) 15. ( ) :/ : :NIM 4 : 2 / 21
87 (2009) 2 Internal Medicine 2 C-7(2) 1 ( ) 4 ( ) / / / / / / / / / 1. 1) ( ) 2) ( ) 3) 4) 5) ( ) 6) 2. 1) 2) 3) 4) 5) : 3 / 2 : 21
88 (2009) C-7(2) 3 Internal Medicine 3 1 ( ) 4 ( ) / / / / 1. 1) 2) 3) 4) 2. 1) 2) 3. 1) 2) 4. 1) 2) : ( ) 2 / 21
89 (2009) C2(2) C3(1) Practice in Physical Chemistry 1 ( ) 2 ( ) / / 1(1 ) 2(2 ) ( ) ( ) 1 (1.0) 2 (1.0) 3 (0.5) ( ) 1. 1) ph 2. 1) 3. 1) 2) 4. 1) 5. 1) () 3. () 4. ( 1) 5. ( 2) 6. ( 1) 7. ( 2) ( , [email protected]) Mail ( : 9:00 12:00 13:00 17:30) (, , [email protected]) Mail ( : 9:00 12:00 13:00 17:30) 89
90 (2009) C-1-(1), C-2-(1), (2), (3), C-3-(1), C-16-(1) - 1 Practice of Physical Chemistry 1 1) :: 1 (0.5)(1.0) 1 (0.5) 2 (0.5) (ph) 3. ph ( ) 2 ( ) / ( ) ( ) ( ) ( , [email protected]) Mail 90
91 (2009) B2(4), C1(1), C3(1), C18(1), (2) 2 Practice in Physical Chemistry 2 1 ( ) 2 ( ) / / 1(1 ) 2 ( 2 ) ( ) ( ) ) 2) 2. 1) 2) 3. 1) 2) 3) 4) ) ( ) 3. () 4. ( 1) 5. ( 2) 6. ( - ) 7. ( -) 8. () ( 4 ) (E )[email protected]( ) ( : 9:00 12:00 13:00 17:30)
92 (2009) C4(3)(4) 1 Organic Chemistry Laboratory (1 3) H NMR 4. IR 5. 1 ( ) 2 ( ) / : ( ) : ( ) ( 6, , [email protected]) Mail ( : ) () ( 6 ) ( ) (E )[email protected] 92
93 (2009) C-5-(1), (2) C-4-(4) 2 Organic Chemistry Laboratory 2 1 ( ) 2 ( ) / / / 2 1 1H NMR 1. / 2. / 3. / 4. / 5. / NMR : :( ) ( ) 93
94 (2009) C6-(2) 3 Organic Chemistry Laboratory 3 1 ( ) 2 ( ) / / / ( ) p- 2. (Aldol ) 3. Indole (Fischer ) 4. (Cannizzaro ) : : ( ) :( ) : - - ( ) [email protected]( ) [email protected]( ) [email protected]( ) 94
95 (2009) C-9-(3) 1 Practice of Biochemistry ) 2) 2. 1) 2) 3) 4) 5) 6) 3. 1) 2) 3) ( ) 2 ( ) / : ( ) ()3 (E )[email protected] ) ( : 95
96 (2009) C-9-(6) C-10-(2) 2 Practice of Biochemistry 2 1 ( ) 2 ( ) / / / / DNA (cloning) ) DNA 2) DNA ) PCR ) 2) ELISA / 1 DNA / 2 DNA / 3 DNA DNA / 4 DNA PCR / 5 () ( 2F) (E )[email protected]( ) yshinoha@gen ome.tokushima-u.ac.jp( ) [email protected]( ) [email protected] ( ) ( : E) 96
97 (2009) C8-(4) 3 Practice of Biochemistry 3 1 ( ) 2 ( ) / / 1. 1) 2) 2. 1) 2) 3) 4) 1. ( 3) :1 (1998) Y=6,300 2 Brock (2003)Michael T. Madigan Y=18,900 3 ( 2 )(2003) Y=2,415 4 Molecular Cell Biology (5th ed.) Lodish (1999) Y=8, ()4 ( : )
98 (2009) C-13-(1,2) 4 Practice of Biochemistry 4 1 ( ) 2 ( ) / / / 4() ()( 3 ) (E )[email protected] [email protected] -u.ac.jp [email protected] ( : ) 98
99 (2009) C7-(1)(2) Pharmacognosy Experiment 1 ( ) 2 ( ) / / ) ( ) 2) ( ) 3) ( ) 4) ( ) 2. 1) ( ) 2) ( ) 3) ( ) 3. 1) ( ) 2) ( ) 3) ( ) 4) ( ) ) ( ) 2) ( ) 1. () ()( 5 ) (E )[email protected] 12:00-13:00) ( :
100 (2009) C13-(1), C13-(4), C13-(5), C16-(3) Practice of Biopharmaceutics 1 ( ) 3 ( ) / / 1 : ph (in situ ) 2: ( ) (in vivo ) 3: P-450 (in vitro ) 4: 7 (in silico ) 1. ( ) 2. ( ) 3. ( ) ( ) ( ) 6. ( ) 7. ( ) 8. ( ) 9. ( ) 10. ( ) 11. ( ) [email protected] : ) ( 100
101 (2009) C-11-(1) C-12-(2) Practice of Health Chemistry 1 ( ) 2 ( ) / / 1. 1) 2) 2. 1) 2) DO, BOD, COD 3. 1) 1. / () / ( ) / () / (DPD ) 2. / DO ( ) / BOD () / COD ( ) 3. / () / () / 4. / () / ( ) / () 5. / ( / TLC ) () 2005 ( ) 1 2 ( ) () ( 3 F ) (E )[email protected] [email protected] kushima-u.ac.jp ( : ) 101
102 (2009) B-(2) Pharmacy Experience 1 ( ) 1 ( ), 2 ( ) 1. 1) 2. 1) 3. 1) 4. 1) 5. 1) AED () ( , [email protected]) Mail ([email protected]) Mail
103 (2009) (I) Pharmacy Practice Pretraining 4 ( ) 4 ( ) 1. 1) 2) 3) 4) 5) ( ) 6) 7) 8) 9) ( ) 10) 11) 2. 1) 103 2) 3) 4) 5) 6) 7) () 8) 9) 10) 11) () 12) () 13) ( ) 14) ( ) 15) 16) 17) 18) ( ) 19) ( ) 20) ( ) 21) ( ) 22) ( ) 3. 1) 2) 3) 4) 5) ( ) 6)
104 (2009) 7) 8) ( ) 9) 10) 11) 12) 13) () 4. 1) 2) 3) 4) 5) 6) 7) ( ) 8) 9) 10) 11) ( ) 12) ( ) 13) 14) ( ) 15) 16) 17) 18) ( ) 19) () 20) ( ) 21) 22) 23) ( ) 24) 25) ( ) 26) 27) 28) 5. 1) 2) 3) 4) 5) 6) 7) 8) 9) 10) ( ) 11) ( ) 6. 1) QOL 2) 3) 4) 5) 6) ( ) 7) () 8) ( ) 9) 10) 11) 12) ( ) ( ) 13) 14) 15) () 104
105 (2009) 16) () 17) ( ) 18) ( ) 7. 1) 1. () (E ) :[email protected] c.jp ( : E )
106 (2009) (II) Pharmacy Practice Hospital Pharmacy 1. 1) 2) 3) 4) 5) 6) 7) ( ) 8) 9) 10) () 11) () 10 ( ) 5 ( ) 12) 13) 14) 15) 16) ( ) 17) ( ) 18) 19) ( ) 20) 21) 22) 23) ( ) 24) () () 25) ( ) 26) () ( ) 27) 28) ( ) ( ) 29) ( ) 30) ( ) 31) 32) () 33) 34) 35) 36) () 106
107 (2009) 37) 38) 39) () ( ) 40) ( ) 41) ( ) 42) () ( ) 43) 44) ( ) 45) 46) ( ) ( ) 47) ( ) 48) 49) 50) 51) 52) ( ) 53) ( ) 54) ( ) 55) () ( ) 2. 1) 2) 3) 4) 5) 6) 7) 8) 9) 10) ( ) 11) 12) ( ) 13) ( ) 14) ( ) 15) ( ) ( ) 16) 17) 18) 3. 1) (DI) 2) 3) 4) 5) 6) 7) 8) MR( ) ( ) 9) DI ( ) 10) ( ) 11) 12) ( ) 13) () 14) ( 107
108 (2009) ) 15) ( ) 4. 1) 2) 3) ( ) 4) 5) ( ) 6) 7) ( ) 8) () 9) 10) ( ) 11) (5W1H) ( ) ( ) 12) ( ) 13) ( ) 14) 15) 16) () 17) ( ) 18) () 19) () 20) () 21) () 22) () 23) ( ) 24) SOAP ( ) 25) () 26) () 27) 28) ( ) 29) ( ) 5. 1) 2) 3) ( () )( ) 4) ()( ) 5) 6) TDM () 7) 8) () 6. 1) 2) ( ) 3) ( ) 4) ( ) 5) ( ) 6) ( ) 7) ( ) 108
109 (2009) 1. ( ) () (E ) :[email protected] c.jp ( : E )
110 (2009) (III) Pharmacy Practice Community Pharmacy 10 ( ) 5 ( ) 1. 1) ( ) 2) 3) 4) 5) 6) 7) 8) 9) 10) 11) ( ) 12) () ) 14) 15) 16) ( ) ( ) 2. 1) 2) 3) ( ) 4) ( ) 5) 6) ( ) () 7) ( ) ( ) 8) ( ) 9) ( ) 10) 11) ( ) 12) ( ) 13) 14) () 15) () 16) ( )
111 (2009) 3. 1) 2) 3) 4) 5) 6) () 7) ( ) 8) 9) 10) () 11) ( ) 12) () 13) ( ) ( ) 14) 15) ( ) 16) () 17) () 18) () 19) () 20) 21) 22) ( ) 23) ( ) 19) 24) 25) 26) 27) 28) 29) ( ) 30) () 31) () ( ) 32) ( ) 33) ( ) 34) () ( ) 35) ( ) 36) ( ) ( ) 37) 38) ( ) 39) 40) () 41) 42) () 43) 44) 45) ( ) 46) 47) 48) ( ) 49) ( ) 50) ( ) 51) ( ) 52) 53) ( ) 54) ( ) ( ) 55) () 111
112 (2009) 56) () 57) () 58) 59) 60) 61) 62) 63) 64) 65) ( ) ( ) 66) 67) 68) () 69) 70) ( ) 71) 72) ( ) 73) ( ) 74) 4. 1) 2) 3) ( ) 4) ( ) 5) () 6) () 7) 8) ( ) 9) 10) 11) () 12) () 13) () 14) () 5. 1) 2) 3) 4) 5) ( ) 6) 7) 8) 9) () 10) 11) 12) 13) 14) 15) 16) 17) 18) () 19) 20) 6. 1) 112
113 (2009) 2) 3) 4) ( ) 5) QOL ( ) 1. ( ) () (E ) :[email protected] c.jp ( : E )
114 (2009) E2 I( ) 1 ( ) 1, 2, 3, 4, 5, 6 / / 1 2 ( ) 1. 1 ( ):90 1 (): 1 ( 8 ) (, , [email protected]) Mail ( : E ) 114 ( , [email protected]) Mail
115 (2009) 1... / 1 ( ) / 1 ( ) / 1 ( ), 2 ( ) / 1 ( ) / 1 ( ) / 3 ( ) / 1 ( ) / 2 ( ) / 3 ( ) / 1 ( ) / 1 ( ) / 1 ( ) / 2 ( ) / 2 ( ) / 2 ( ) / 2 ( ) / 3 ( ) / 2 ( ) / 2 ( ) / 3 ( ) / 1 ( ) / 1 ( ) / 2 ( ) / 1 ( ) / 1 ( ) / 2 ( ) / 3 ( ) / 3 ( ) / 1 ( ) / 3 ( ) / 3 ( ) / 2 ( ) / 2 ( ) / 3 ( ) / 1 ( ) / 2 ( ) / 2 ( ) / 3 ( ) / 3 ( ) / 3 ( ) / 3 ( ) / 4 ( ) / 4 ( ) / 3 ( ) / 1 ( ) / 2 ( ) / 3 ( ) / 1 ( ) / 3 ( ) / 2 ( ) / 3 ( ) / 2 ( ) / 3 ( ) / 2 ( ) ()... / 3 ( ) / 3 ( ) / 3 ( ) / 3 ( ) / 3 ( )
116 (2009) 2... / 3 ( ) / 4 ( ) / 4 ( ) / 4 ( ) / 2 ( ) / 2 ( ) / 2 ( ) / / / / 2 ( ) / 2 ( ) / 2 ( ) / 2 ( ) / 2 ( ) / 3 ( ) / 2 ( ) / 1 ( ), 2 ( )
117 (2009) A-(1) 1 Introduction to Pharmaceutical Sciences 1 1 ( ) 1 ( ) / / 1. 1) 2. 1) QOL 3. 1) ( ) 1. 1 ( ) 2. 2 ( ) 3. 3 ( ) 4. 4 ( ) 5. 5 ( ) 6. 6 ( ) 7. 1 ( ) 8. 1 ( ) 9. 2 ( ) ( ) ( ) ( ) ( ) ( ) 15. ( ) (): ([email protected]) Mail ( B 3, , [email protected] -u.ac.jp) Mail 117
118 (2009) A-(2),(3) 2 Introduction to Pharmaceutical Sciences 2 1 ( ) 1 ( ) / / / 1. 1) a. b. c. 2) 3) 4) 5) 6) 7) 8) 2. 1) 2) 3) 4) 5) 6) 7)
119 (2009) ( , Mail (, , Mail ( , Mail 119
120 (2009) B(1) 3 Guide to Pharmacy 3 1 ( ) 1 ( ), 2 ( ) ( 2 ) () 1. 1) 1. ( ) 2) 3) 4) 5) 2. 1) 2) 3. 1) 4. 1) 2) 3) 5. 1) 2) ) 2) (, , [email protected]) Mail ( 2, , [email protected]) Mail ( : 5 7 ) ( , [email protected]) Mail ( : ) ([email protected]) Mail ( , [email protected]) Mail ( 6, , [email protected]) Mail ( : ) ( 4F, , [email protected] shima-u.ac.jp) Mail ( , [email protected]) Mail ( , [email protected]) Mail (, , [email protected]) Mail ( : 8:30 17:30) ( , [email protected]) Mail (, , [email protected]) Mail ( : (9:00-16:00)) ( , [email protected]) Mail ([email protected]) Mail
121 (2009) C1(1) 1 Physical Chemistry ) 2) (1 ) 3) 4) 5) ( ) 6) 2. 1) () 2) van der Waals 1 ( ) 1 ( ) / 3) 4) 5) 1. ( ) 2. ( ) 3. Schrodinger (1) ( ) 4. Schrodinger (2) ( ) 5. (1) ( ) 6. (2) ( ) 7. ( ) 8. Pauli ( ) 9. ( ) 10. ( ) 11. ( ) 12. ( ) 13. Huckel ( ) 14. (1) ( ) 15. (2) ( ) () ( 4 ) (E )[email protected]( ) ( : 9:00 12:00 13:00 17:30( )) 121
122 (2009) C1(2), C2(3) 2 Physical Chemistry 2 1 ( ) 1 ( ) / 1. ( ) 1) 2. 1) 2) 3) 4) 5) ( ) 6) 7) 8) 3. 1) 2) 3) 4) 5) 6) 7) 8) ) (Clausius-Clapeyron ) 2) 3) ( ) 5. 1) 2) (1) 5. (2) 6. (1) 7. (2) (1) 11. (2) ( ) (, , [email protected]) Mail ( : 8:30 12:00 13:00 17:30) [email protected] 2 ( )
123 (2009) C1(3) (4) 3 Physical Chemistry 3 2 (1.0) 1 (0.5) 1. 1) 2) ( ) 2. 1) 2) 3) 4) 5) 6) (Debye-Hückel ) 3. 1) 2) 3) 4) Nernst 5) 4. 1) (1) 3. (2) (1) 7. (2) 8. (1) 9. (2) 10. (1) 11. (2) 12. (1) 13. (2) 14. (1) 15. (2) ( ) 3 ( ) / ( ) (, , [email protected]) Mail ( : 8:30 12:00 13:00 17:30) [email protected] 3 ( ) 123
124 (2009) C1(3), C2(1) (2) 1 Analytical Chemistry 1 1) ( ) 2) ( ) 3 (0.5)(0.5) (0.5) 1. 1) 2) SI() 3) 4) 2. 1) 2) ph ( ) 3) 4) (Mohr Fajans Volhard ) 5) ( ) 6. 2(pH) ( ) ( ) 1 ( ) / ( ) (, , [email protected]) Mail ( : 8:30 12:00 13:00 17:30) [email protected] 1 ( ) 124
125 (2009) C1(1), C2(2) (3), C3(1) 2 Analytical Chemistry ) 2. 1) () 2) Lambert - Beer 3) 3. 1) ( ) 2) 3) 4. ( ) 1) 2) 3) ( ) 5. 1) 1 ( ) 2 ( ) / 2) ORD / CD 3) ORD / CD 1. ( ) 2. ( ) 3. (1) ( ) 4. (2) ( ) 5. (3) ( ) 6. (1) ( ) 7. (2) ( ) 8. (3) ( ) 9. ( ) (1) ( ) 10. ( ) (2) ( ) 11. (1) ( ) 12. (2) ( ) 13. (3) ( ) 14. (4) ( ) () () ( 4 ) (E )[email protected]( ) ( : 9:00 12:00 13:00 17:30( )) 125
126 (2009) C2(1) (2) (3) 3 Analytical Chemistry ) 2) 3) 4) 2. 1) 2) 3. 1) 2) 4. 1) 2) 5. 1) 1. 1) 2. 2) 3. 1) 4. 2) 5. 3) 6. 1) 7. 2) ( ) 8. 3) 9. 4) 10. 5) 11. 1) 12. 2) 13. 3) ( ) 3 ( ) / :( 4) ( : 12:00-17:30 E ) 126
127 (2009) C-4-(1) 1 Basic Organic Chemistry C4 (1) (2) (3) (4) () ( ) ( ) 1 ( ) / 15. Fischer Newman () Saytzev Hofmann Markovnikov
128 (2009) ( 4 ) ( 6, , [email protected]) Mail ( : ) () ( 6 ) ( ) (E )[email protected] 128
129 (2009) C-4-(2) 2 Basic Organic Chemistry II 1 ( ) 1 ( ) / ( ) ( ) Base 1. 1) 2. 1) 2) 3) 4) 1. (1) 2. (2) 3. (3) 4. (4) 5. (1) 6. (2) 7. (1) 8. (2) 9. (1) 10. (2) 11. (3) 12. (4) 13. (1) 14. (2) () 6( ) (E ) [email protected]( ) ) ( :
130 (2009) C-4-(3) 3 Basic Organic Chemistry 3?? ( ) () 3 1 (1.0) 2 (1.0) 1 (1.0) 2 (1.0) () (SN1 SN2 ) 3. (Saytzev ) ( ) 1 ( ) / SN2 ( 6 ) 2. SN2 ( ) 3. SN2 4. SN1 ( 7 ) 5. SN1 / ( ) 6. Hammond 7. SN1 8. ( 9 ) 9. E1 ( 7 ) 10. E1 11. Saytzev 12. E2 ( 7 ) 13. E2 14. () 15. ( 8 ) 16. : I II III ()( 6) (E )[email protected],jp ) ( : 130
131 (2009) C4-(4) 4 Organic Chemistry 4 1 ( ) 2 ( ) / (NMR) (IR) H-NMR 3. H-NMR 1 4. H-NMR 2 5. C-NMR 6. C-NMR 7. IR 8. UV 9. MASS 10. X 11. CD ( ) () 3F (E )[email protected]
132 (2009) C-5-(1) 1 Applied Organic Chemistry 1 1 ( ) 2 ( ) / 1 (1.0) 2 (1.0) 3 (1.0) 2 (0.5) ( ) Claisen 10. β- 11. α- 12. α,β- 13. / ( ) WEB ( , [email protected]) Mail ( : )
133 (2009) C-5-(2) 2 Applied Organic Chemistry ) 2) 2. 1) ) () 5. -3( ) ( ) ( ) ( ) 2 ( ) / ()(4 ) (E )[email protected] ( : 12 :00 13 :00) 133
134 (2009) C-6-(1) Bio-organic Chemistry 1 ( ) 2 ( ) /? 1. 1) 2) 3) 4) 2. 1) 3. 1) 2) 1. (1) 2. (2) 3. (1) (2) 5. (3) 6. (1) 7. (2) 8. (3) 9. (4) 10. (1) 11. (2) 12. (3) 13. (1) 14. (2) 15. Chemical Biology () 6 ( ) (E )[email protected]( ) ) ( :
135 (2009) C-6-(2) Medicinal Organic Chemistry ( ) C6 (2) 1. ( ) ( ) 3 ( ) / DNA β : II ( 6, , [email protected]) Mail ( : ) () ( 6 ) ( ) (E )[email protected] 135
136 (2009) C-7-(1) 1 Natural Medicines 1 1 ( ) 2 ( ) / 1. 1) 2) 2. 1) 2) 3) 3. 1) 2) ) ) 2) (1) 4. (2) (1) / (2) / (3) / ( ) ()( 5 ) (E )[email protected] 12 :00 13 :00) ( :
137 (2009) C-7(2) 2 Natural Medicines 2 1 ( ) 2 ( ) / / () () 1. 1) 2) 3) 2. 1) 2) 3. 1) 2) 3) (1) 4. (2) (1) / (1) 7. (2) / (2) 8. (3) / (3) 9. (4) / 10. (5) / 11. (6) / 12. (7) / 13. / 14. / 15. / 16. ( ) ()( 5 ) (E )[email protected] [email protected] ( : 12 :00 13 :00) 137
138 (2009) C-7-(3) 3 Natural Medicines 3 1 ( ) 3 ( ) / ) 2) 3) 4) 5) 6) 7) 2. 1) 2) L III ()( 5 ) (E )[email protected] 12 :00 13 :00) ( :
139 (2009) C8 (2) 1 Biopharmacy ) 2) 2. 1) 2) 3) 3. 1) ( ) 4. 1) 2) 3) 4) 5. 1) 2) ( ) 1 ( ) / ( 5 ) ( , [email protected]) Mail ( : ) 139
140 (2009) C8-(1) 2 Biopharmacy ) 2. 1) 3. 1) 4. 1) 5. 1) 6. 1) 7. 1) 8. 1) 1 ( ) 1 ( ) / 9. 1),, 1. 1 : ( ), ( ) () (4)TEL: (E )[email protected] ( : 12:00-13:00) 140
141 (2009) C8(4) 3 Biopharmacy 3 ( 2 ) () 1. 1) 2) 2. 1) 2) 3) 4) 5) 6) () 3. 1) 4. 1) 2) 3) 5. 1) 1 ( ) 2 ( ) 1. 1) (30 ) 2) (10 ) 3) (10 )
142 (2009) C-9-(1)(2) 1 Biochemistry 1 1 ( ) 1 ( ) / DNA ( ) ) 2) 2. 1) 2) 3. 1) 4. 1) DNA RNA 2) () 5. 1) 2) DNA RNA 3) 4) 5) ( ) 6) RNA ) DNA RNA 2) 3) RNA 4) RNA 5) 7. 1) DNA 2) ( ) 3) DNA 8. 1) (SNPs) DNA RNA 4. DNA 5. DNA () : : 8,190 ( 7,800 )
143 (2009) 4. ) ( : 143
144 (2009) C9 (3) 2 Biochemistry 2 1 ( ) 1 ( ) / 1. 1) 2) 3) 2. 1) 2) 3) 4) 5) 3. 1) ( ) 2) 3) 4) 5) 4. 1) 2) 1. (Edman ) 2., α β β, ,, 4. (1) 5. (2) ,, ( ) 9. () 10. (, Km, Vmax, ) 11. ( ) 12. () 13. (, Allosetric Enzyme) ( ) ()3 (E ) [email protected] ) ( :
145 (2009) C-9-(4) 3 Biochemistry 3 1 ( ) 2 ( ) / ) 2. ATP 1) ATP 2) 3) 4) (. 5) β- 6) CoA 7) 8) ATP 9) 10) 3. 1) 2) 3) ( ) 4) 5) 6) 145 7) 8) 9) 4. 1) 2) (1) 6. (2) 7. (3) (1) 10. (2) 11. (3) 12. (1) 13. (2) ( : ) () ( 3 ) (E )[email protected] ) ( :
146 (2009) C9(5) 4 Biochemistry 4 1 ( ) 3 ( ) / 1. 1) 2) 3) 4) 2. 1) 2) 3) ( ) 4) ( ) 5) () 6) 3. 1) 2) 146 3) 4) 4. 1) 2) 3) 5. 1) 2) G 3) 4) ( ) 1., , 5. 6., NO, G - 9. G G - C 11. G TGF 13. Ras-MAPK 14. PI3-Kinase (AKT)
147 (2009) 5 () : ( ) 5 : () ()( 3 ) (E )[email protected] ) ( : 147
148 (2009) C9(2),(6) Gene Technology 1 ( ) 3 ( ) / DNA RNA DNA 1. 1) ( ) 2) 3) 4) ( ) 2. 1) DNA RNA 2) DNA RNA 3) 4) RNA 3. 1) 2) cdna DNA ) RNA 1 ( 5 )H. Lodish, A. Berk, C.A. Kaiser, M.Krieger, M.P. Scott, P. Matsudaira, S. L. Zipursky, J. Darnell, (2005) () () ( 2 ) (E )[email protected] ( : E)
149 (2009) C-10-(1) 1 Cell Biology 1 1 ( ) 1 ( ) / 1. 1) 2) - 3) 4) ( ) 5) 6) 2. 1) 2) 3) 4) 3. 1) 2) MHC 3) T 4) T ( ) 5) () 9. (1) BCR TCR 10. (2) TCR MHC ( ) 4, ( )3, [email protected] ( : )
150 (2009) C10(2) 2 Cell Biology 2 1 ( ) 3 ( ) / (1) 3. (2) [email protected] 150
151 (2009) C10(3) 3 Cell Biology 3 ( 2 ) () 1. 1) DNA (EB B19 B ) 2) RNA ( A C ) 3) (HIV HTLV) 4) () 5) ( ) 6) ( ) 7) ( ) 1 ( ) 3 ( ) 8) () 9) ( ) 10) 11) ( ) 12) 13) 2. 1) 1. 1) (30 ) 2) (10 ) 3) (10 )
152 (2009) C-11- (2),(3) 1 Pharmaceutical Health Sciences 1 1 ( ) 2 ( ) / / ( ) 1. 1) () 2) 2. 1) 2) 3) 3. 1) 2) (WHO) 4. 1) 2) 5. 1) 2) 152 3) 4) 6. 1) 2). 3) 4) 7. 1) 2) 8. 1) 2) () 3) () 4) 5) () ( )
153 (2009) ( ) ()( 3 ) (E )[email protected] ) ( : 153
154 (2009) C-11- (1) 2 Pharmaceutical Health Sciences 2 1 ( ) 2 ( ) / ( ) ( ) ) 2) 3) 2. 1) 2) (Ames ) 3) 3. 1) 2) PCB 3) 4) (NOAEL) 154 5) (1 ) 6) () 7) () 4. 1) 5. 1) 2) 3) 4) () 5) 6) 7) 8) 9) 6. 1) 2) 3) 4) ( ) (1) 5. (2) (1)
155 (2009) 8. (2) (1) 11. (2) (1) 14. (2) ( ) ()( 3 ) (E )[email protected] ) ( : 155
156 (2009) C-12-(1) (2) Environmental Pharmacy 1 ( ) 3 ( ) / : 1. 1) 2) 3) 4) 5) 6) 2. 1) 2) 3) 4) 5) 6) 7) 3. 1) 2) 156 3) 4) () 4. 1) 2) 3) 4) 5. 1) 2) 3) 6. 1) 2) 3) 4) PRTR 7. 1) 2) 3) 4)
157 (2009) PRTR () ( 3 ) (E )[email protected] ) ( : 157
158 (2009) C13-(1) 1 Basic Clinical Pharmacy 1 1 ( ) 1 ( ) / 1. 1) () 2) ( ) 3) ( ) 4) 5) 6) 7) 2. 1) 2) 3) 4) 5) 6) 7) ) ( ) 2) 3) 4. C13-(1) 1. / 2. / 3. / 4. / 5. / 6. / 7. / 8. / 9. / 10. / / 11. / 12. / 13. / 14. / 15. /
159 (2009) ( 4 ) 1( ) [email protected] : ) ( 159
160 (2009) C8-(3), C13-(2) 2 Basic Clinical Pharmacy 2 1 ( ) 2 ( ) / ( ) 1. 1) 2. 1) 2) 3) ( ) (2,400 + ) ( ) (7,600 + ) ()( 3 ) (E )[email protected] ( : )
161 (2009) C8-(3), C13-(2), (3) 3 Basic Clinical Pharmacy 3 2 ( ) 1. 1) ( ) 2 ( ) / 5 ( ) (2,400 + ) ( ) (7,600 + ) () (3 ) (E )[email protected] ( : ) 161
162 (2009) C13-(4) 4 Basic Clinical Pharmacy 4 1 ( ) 3 ( ) / 1. 1) 2) 3) ( ) 4) 5) 6) 2. 1) 2) - 3) 4) ( ) 5) () 6) 7) 3. 1) 2) 3) 4) P ) 6) 7) (SNPs ) 8) 9) 4. 1) 2) 3) 4) 5) 6) 7) 5. 1) 2) 1. I [email protected] : ) (
163 (2009) C13-(5) 5 Basic Clinical Pharmacy 5 TDM 1 (1.0) 4 (0.5) 1. 1) 2) 3) 1-4) 2-5) 6) 7) 8) 9) 10) 11) 12) 2. TDM (Therapeutic Drug Monitoring) 1) (TDM) 2) TDM 3) 4) 5) 1 ( ) 3 ( ) / 1. (1 ) / 2. AUC (1 ) / (AUC) (1 ) / (1 ) / 1-0 ( ) 5. 1 (1 ) / 1-1 ( ) 6. (2 ) / 1-7. (2 ) / (2 ) / () 9. (2 ) / 10. TDM(2 ) / TDM ( 4 ) 163
164 (2009) : ) ( 164
165 (2009) C14-(1)(2) 1 Pharmacotherapy 1 1 ( ) 3 ( ) / Practical pharmacy 1. 1) 2) 2. 1) 2) 3. 1) 2) 4. 1) 2) ) 2) 1. (1) 2. (2) II ()2 (E )[email protected] ( : )
166 (2009) C-14-(3) 2 Pharmacotherapy 2 aaa 1. 1) ( ) 2) 3) 4) 5) 6) 1 ( ) 3 ( ) / 2. 1) 2) 3) 4) 3. 1) 2) 3) 4. 1) 2) () 3) () 5. 1) 2) 3) 6. 1) 166
167 (2009) 2) 3) 4) 5) 6) 1. () 2. () 3. () 4. () 5. ( ) ( ) 8. ( ) 9. ( 1) 10. ( 2) 11. () 12. ( ) 13. ( ) 14. ( - ) 15. ( ) II (1) ()2 (E )[email protected] ( : E ) 167
168 (2009) C14-(4) 3 Pharmacotherapy 3 1 ( ) 4 ( ) / 1. (SBO58,59) 2. ( ) (SBO 60,61) 3. (SBO62, 63) 4. (SBO64) 5. (1) (SBO65, 66)) 6. (2) (SBO67, 68) 7. (1) (SBO69,70) 8. (2) (SBO70-72) 9. (1) (SBO73,74) 10. (2) (SBO75,76) 11. (SBO77,78) 12. (SBO79) 13. (SBO80) (SBO82, 83) 15. (SBO84) 16. 3,, II. (1), () ( )5 (E )[email protected] ( : ) 21
169 (2009) C14(5) 4 Pharmacotherapy 4 1 ( ) 4 ( ) / ( , [email protected]) Mail 21
170 (2009) C-15-(1),(2) 1 Drug Informatics 1 () () 1. 1) 2) 3) 2. 1) 2) 3) 4) 3. 1) 4. EBM(Evidence-Based Medicine) 1 ( ) 3 ( ) / 1) EBM EBM 5. 1) (POS) EBM ICT : ( , [email protected]) Mail 170
171 (2009) C-16-(1),(2) 1 Physical Pharmacy 1 1 ( ) 1 ( ) / 1 2 () 1 (0.5) 2 (0.5) ) 171 2) 3) 4) 2. 1) 2) 3) 4) 5) 3. 1) 2) 3) 4) 5) 6) 7) X 4. 1) 2) 3) 5. 1) 6. 1)
172 (2009) ( ) ( , [email protected]) Mail 172
173 (2009) C-1-(4), C-16-(3) 2 Physical Pharmacy 2 1 ( ) 2 ( ) / DDS (Drug Delivery System DDS, ), DDS 1 (0.5) 1 (0.5) DDS DDS 1) 2) DDS 3. 1) ( ) 2) 3) 4) 5) 6) 4. 1) 2) 5. 1) DDS 1) () 9. DDS DDS 15. (DDS) 16. ( ) () ( ) ( ) () ( 5 ) (E )[email protected] 12:00-13:00) ( :
174 (2009) B(1), C2(2) Japanese Pharmacopoeia 1 ( ) 3 ( ) / / 1. 1) 2. 1) 2) 3) 4) ( ) 8. ( 1) 9. ( 2) 10. () 11. ( 1) 12. ( 2) 13. ( 1) 14. ( 2) , ( , [email protected]) Mail ( : 8:30 12:00 13:00 17:30) (, , [email protected]) Mail ( : 8:30 12:00 13:00 17:30) 174
175 (2009) C-17-(1), (2) 1 Drug Development 1 1 ( ) 1 ( ) / () (3F) (E )[email protected] ( : )
176 (2009) C-17-(3), (4) 2 Drug Development 2 1 ( ) 3 ( ) / 1. 1) 2. 1) 3. 1) 1. (1) 2. (2) 3. (1) 4. (2) 5. (1) 6. (2) 7. (1) 8. (2) 9. (3) 10. (4) 11. (5) 12. (6) 13. (7) 14. (1) 15. (2) () 6 ( ) (E )[email protected]( ) ( : )
177 (2009) C-17-(5) 3 Drug Development 3 1 ( ) 2 ( ) / / (CRC) ( GCP ) 1. 1) 2) 3) 4) () ( ) ( ) 5) ( ) 2. 1) ( I II III ) 2) ( ) 3. 1) (t- Mann-Whitney U ) χ2 (Dunnett Tukey ) 2) ( 177
178 (2009) ) () (Kaplan-Meier ) 1. / 2. / 3. / 4. / 5. / 6. / 7. / 8. / 9. / 10. / 11. / 12. / 13. /, 14. / 15. () () ( : E ) ( : E ) 178
179 (2009) C 18-(1),(2) 1 Social Pharmacy 1 1 ( ) 3 ( ) ) 2) 2. 1) 2) 3) 4) 5) 6) 7) 8) 3. 1) 179 2) 3) 4) 4. 1) ( ) 2) OTC 1. ( ) 4,700 ( ) : ( 5671) : E : k [email protected]
180 (2009) 1 English for Pharmaceutical Sciences 1 1 ( ) 2 ( ) 1. 1) 2) 2. 1) 2) 3. 1) 2) 1. (, , [email protected]) Mail ( 2, , [email protected]) Mail ( : 5 7 ) ( , [email protected]) Mail ( : ) ([email protected]) Mail ( , [email protected]) Mail ( , [email protected]) Mail ( 4F, , [email protected] shima-u.ac.jp) Mail 180 ( , [email protected]) Mail ( , [email protected]) Mail (, , [email protected]) Mail ( : 8:30 17:30) ( , [email protected]) Mail (, , [email protected]) Mail ( : (9:00-16:00)) ( , [email protected]) Mail ([email protected]) Mail
181 (2009) 2 English for Pharmaceutical Sciences ) 2) 2. 1) 2) 3. 1) 2) (, , [email protected]) Mail ( 2, , [email protected]) Mail ( : 5 7 ) ( , [email protected]) Mail ( : ) ([email protected]) Mail ( , [email protected]) Mail ( 6, , [email protected]) Mail ( : ) 1 ( ) 3 ( ) ( 4F, , [email protected] shima-u.ac.jp) Mail ( , [email protected]) Mail ( , [email protected]) Mail (, , [email protected]) Mail ( : 8:30 17:30) ( , [email protected]) Mail (, , [email protected]) Mail ( : (9:00-16:00)) ( , [email protected]) Mail ([email protected]) Mail 181
182 (2009) C3(2) Structural Biology 1 ( ) 2 ( ) / 1. ( ) [email protected] 182
183 (2009) C1(1) (2) (4) C3(2) C4(1) (2) C6(1) (2) () Pharmacoinformatics 1 ( ) 3 ( ) / - () ) 2) 3) 4) 2. 1) ( ) 2) 3. 1) Hammett 2) 3) 4. 1) (1) 3. - (2) (1) 6. (2) 7. (3) 8. (1) 9. (2) ( ) 10. (1) 11. (2) 12. (3) 13. (4) ( ) 14. (5) ( )() ( 4 ) (E )[email protected]( ) ( : 9:00 12:00 13:00 17:30)
184 (2009) C-4-(1) Inorganic Chemistry 1 ( ) 3 ( ) / 1 (0.5) ( ) 1. 1) 2) 3) 4) 2. 1) 2) 3) 4) 3. 1) 2) 3) 4) 5) 6) 7) ) 2) 3) 4) 5) 5. 1) 2) 3) 4) 5) () 6) 7)
185 (2009) ( ) ( ) () ( 5 ) (E )[email protected] 12:00-13:00) ( : 185
186 (2009) C-6-(2) 1 Medicinal Chemistry 1 1 ( ) 3 ( ) / ( ) ( ) () ( ) 1 (1.0) 2 (1.0) 3 (1.0) 2 (1.0)(1.0) 1 (1.0) ( ) / 2. / 1 3. / 2 4. / 3 5. / 6. HMG-CoA / 1 7. HMG-CoA / 2 8. H2 / 1 9. H2 / ( ) / ( ) / / 13. / 14. / / : :; ( , [email protected]) Mail ( : )
187 (2009) C-17-(2) 2 Medicinal Chemistry 2 1 ( ) 3 ( ) / 1. 1) 2. 1) ( ) 4. -2( ) 5. -1() 6. -2( ) 7. -3( ) 8. -4( ) ( ) ( ) ( ) ( ) ( ) ( ) : () 4 ( ) (E )[email protected]( ) ) ( :
188 (2009) 1 Developmental Pharmacy 1 1 ( ) 3 ( ) / 1. 1) 2. 1) 3. 1) 4. 1) ( , [email protected]) Mail
189 (2009) C-5-(2) 2 Developmental Pharmacy ) () 2. 1) 2) ( ) ( ) 3 ( ) / ()(4 ) (E )[email protected] ( : 12:00 13:00) 189
190 (2009) C17( 3 ) 3 Developmental Pharmacy 3 1 ( ) 4 ( ) / 21 DNA RNA 1. 1) 2) 3) 4) 5) (SNPs) 6) 2. 1) 2) 3) 3. 1) ( ) 2) ) 2) 3) 4) RNA 5) 6) () () ( 2 ) (E )[email protected] ( : E- ) 21
191 (2009) C-17-(1) (5) Process Chemistry 1. 1) 2. 1) 2) 3) E- 3. 1) 2) 4. 1) 2) ( ( )) ( ) 13. ( ) 14. ( ) ( ) 4 ( ) / 2, ()(4 ) (E )[email protected] ( : 12 :00 13 :00)
192 (2009) C-16-(1) C-1(4) Medicinal Polymer Chemistry 1 ( ) 4 ( ) / Donnan ( ) DDS JP 2 (0.5) 3 (0.5) 1 (0.5) 2 (0.5) ) 2) ) 2) 3. Characterization 1) 2) ( ) 4. 1) 2) Donnan 5. 1) 2) 3) DDS 4) 6. 1) JP 2) JP Characterization 1 7. Characterization Donnan JP
193 (2009) ( ) ( , [email protected]) Mail
194 (2009) C2(2) C3(1) Practice in Physical Chemistry 1 ( ) 2 ( ) / / 1(1 ) 2(2 ) ( ) ( ) 1 (1.0) 2 (1.0) 3 (0.5) ( ) 1. 1) ph 2. 1) 3. 1) 2) 4. 1) 5. 1) () 3. () 4. ( 1) 5. ( 2) 6. ( 1) 7. ( 2) ( , [email protected]) Mail ( : 9:00 12:00 13:00 17:30) (, , [email protected]) Mail ( : 9:00 12:00 13:00 17:30) 194
195 (2009) C-1-(1), C-2-(1), (2), (3), C-3-(1), C-16-(1) - 1 Practice of Physical Chemistry 1 1) :: 1 (0.5)(1.0) 1 (0.5) 2 (0.5) (ph) 3. ph ( ) 2 ( ) / ( ) ( ) ( ) ( , [email protected]) Mail 195
196 (2009) B2(4), C1(1), C3(1), C18(1), (2) 2 Practice in Physical Chemistry 2 1 ( ) 2 ( ) / / 1(1 ) 2 ( 2 ) ( ) ( ) ) 2) 2. 1) 2) 3. 1) 2) 3) 4) ) ( ) 3. () 4. ( 1) 5. ( 2) 6. ( - ) 7. ( -) 8. () ( 4 ) (E )[email protected]( ) ( : 9:00 12:00 13:00 17:30)
197 (2009) C4(3)(4) 1 Organic Chemistry Laboratory (1 3) H NMR 4. IR 5. 1 ( ) 2 / : ( ) : ( ) ( 6, , [email protected]) Mail ( : ) () ( 6 ) ( ) (E )[email protected] 197
198 (2009) C-5-(1), (2) C-4-(4) 2 Organic Chemistry Laboratory 2 1 ( ) 2 / / / 2 1 1H NMR 1. / 2. / 3. / 4. / 5. / NMR : :( ) ( ) 198
199 (2009) C6-(2) 3 Organic Chemistry Laboratory 3 1 ( ) 2 / / / ( ) p- 2. (Aldol ) 3. Indole (Fischer ) 4. (Cannizzaro ) : : ( ) :( ) : - - ( ) [email protected]( ) [email protected]( ) [email protected]( ) 199
200 (2009) C-9-(3) 1 Practice of Biochemistry ) 2) 2. 1) 2) 3) 4) 5) 6) 3. 1) 2) 3) ( ) 2 ( ) / : ( ) ()3 (E )[email protected] ) ( : 200
201 (2009) C-9-(6) C-10-(2) 2 Practice of Biochemistry 2 1 ( ) 2 ( ) / / / / DNA (cloning) ) DNA 2) DNA ) PCR ) 2) ELISA / 1 DNA / 2 DNA / 3 DNA DNA / 4 DNA PCR / 5 () ( 2F) (E )[email protected]( ) yshinoha@gen ome.tokushima-u.ac.jp( ) [email protected]( ) [email protected] ( ) ( : E) 201
202 (2009) C8-(4) 3 Practice of Biochemistry 3 1 ( ) 2 ( ) / / 1. 1) 2) 2. 1) 2) 3) 4) 1. ( 3) :1 (1998) Y=6,300 2 Brock (2003)Michael T. Madigan Y=18,900 3 ( 2 )(2003) Y=2,415 4 Molecular Cell Biology (5th ed.) Lodish (1999) Y=8, ()4 ( : )
203 (2009) C-13-(1,2) 4 Practice of Biochemistry 4 1 ( ) 2 ( ) / / / 4() ()( 3 ) (E )[email protected] [email protected] -u.ac.jp [email protected] ( : ) 203
204 (2009) C7-(1)(2) Pharmacognosy Experiment 1 ( ) 2 ( ) / / ) ( ) 2) ( ) 3) ( ) 4) ( ) 2. 1) ( ) 2) ( ) 3) ( ) 3. 1) ( ) 2) ( ) 3) ( ) 4) ( ) ) ( ) 2) ( ) 1. () ()( 5 ) (E )[email protected] 12:00-13:00) ( :
205 (2009) C13-(1), C13-(4), C13-(5), C16-(3) Practice of Biopharmaceutics 1 ( ) 3 ( ) / / 1 : ph (in situ ) 2: ( ) (in vivo ) 3: P-450 (in vitro ) 4: 7 (in silico ) 1. ( ) 2. ( ) 3. ( ) ( ) ( ) 6. ( ) 7. ( ) 8. ( ) 9. ( ) 10. ( ) 11. ( ) [email protected] : ) ( 205
206 (2009) C-11-(1) C-12-(2) Practice of Health Chemistry 1 ( ) 2 ( ) / / 1. 1) 2) 2. 1) 2) DO, BOD, COD 3. 1) 1. / () / ( ) / () / (DPD ) 2. / DO ( ) / BOD () / COD ( ) 3. / () / () / 4. / () / ( ) / () 5. / ( / TLC ) () 2005 ( ) 1 2 ( ) () ( 3 F ) (E )[email protected] [email protected] kushima-u.ac.jp ( : ) 206
207 (2009) B-(2) Pharmacy Experience 1 ( ) 1 ( ), 2 ( ) 1. 1) 2. 1) 3. 1) 4. 1) 5. 1) AED () ( , [email protected]) Mail ([email protected]) Mail
208 (2009) 1... / 1 ( ) / 1 ( ) / 1 ( ), 2 ( ) / 1 ( ) / 1 ( ) / 3 ( ) / 1 ( ) / 2 ( ) / 3 ( ) / 1 ( ) / 1 ( ) / 1 ( ) / 2 ( ) / 2 ( ) / 2 ( ) / 2 ( ) / 3 ( ) / 2 ( ) / 2 ( ) / 3 ( ) / 1 ( ) / 1 ( ) / 2 ( ) / 1 ( ) / 1 ( ) / 2 ( ) / 3 ( ) / 4 ( ) / 3 ( )
209 (2009) 1... / 1 ( ) / 3 ( ) / 3 ( ) / 2 ( ) / 2 ( ) / 3 ( ) / 1 ( ) / 2 ( ) / 2 ( ) / 3 ( ) / 3 ( ) / 3 ( ) / 3 ( ) / 4 ( ) / 4 ( ) / 3 ( ) / 3 ( ) / 1 ( ) / 2 ( ) / 3 ( ) / 1 ( ) / 3 ( ) / 2 ( ) / 3 ( ) / 4 ( ) / 4 ( ) / 4 ( ) / 2 ( ) / 3 ( ) / 3 ( ) / 3 ( ) / 4 ( )
210 (2009)... / 4 ( ) / 2 ( ) / 4 ( ) ()... / 3 ( ) / 3 ( ) / 4 ( ) / 3 ( ) / 4 ( ) / 4 ( ) / 4 ( ) / 4 ( ) / 2 ( ) / 2 ( ) / 2 ( ) / 2 ( ) / 2 ( ) / 2 ( ) / 2 ( ) / 2 ( ) / 2 ( ) / 2 ( ) / 2 ( ) / 3 ( ) / 2 ( ) / 1 ( ), 2 ( ) / 4 ( ) / 5 ( ) / 5 ( )
211 (2009) I( )... / 1, 2, 3, 4, 5, / 1 ( ) / 1 ( ) / 1 ( ), 2 ( ) / 1 ( ) / 1 ( ) / 3 ( ) / 1 ( ) / 2 ( ) / 3 ( ) / 1 ( ) / 1 ( ) / 1 ( ) / 2 ( ) / 2 ( ) / 2 ( ) / 2 ( ) / 3 ( ) / 2 ( ) / 2 ( ) / 3 ( ) / 1 ( ) / 1 ( ) / 2 ( ) / 1 ( ) / 1 ( ) / 2 ( )
212 (2009) 4... / 3 ( ) / 3 ( ) / 1 ( ) / 3 ( ) / 3 ( ) / 2 ( ) / 2 ( ) / 3 ( ) / 1 ( ) / 2 ( ) / 2 ( ) / 3 ( ) / 3 ( ) / 3 ( ) / 3 ( ) / 4 ( ) / 4 ( ) / 3 ( ) / 1 ( ) / 2 ( ) / 3 ( ) / 1 ( ) / 3 ( ) / 2 ( ) / 3 ( ) / 2 ( ) / 3 ( ) / 2 ( ) ()... / 3 ( ) / 3 ( ) / 3 ( ) / 3 ( )
213 (2009) 1... / 3 ( ) / 3 ( ) / 4 ( ) / 4 ( ) / 4 ( ) / 2 ( ) / 2 ( ) / 2 ( ) / / / / 2 ( ) / 2 ( ) / 2 ( ) / 2 ( ) / 2 ( ) / 3 ( ) / 2 ( ) / 1 ( ), 2 ( )
2009年度 東京薬科大学 薬学部 授業計画
2009 2 234 Tokyo University of Pharmacy and Life Sciences since 880 Tokyo University of Pharmacy and Life Sciences Department of Clinical Pharmacy Men's Division Department of Clinical Applied Pharmacy
2 English III Lecture Ready 1 Exploring Content 2 English IV Lecture Ready 1 Exploring Content 2 Microbiology II Chemistry of Biomolecules II Enzymology Biochemistry of Metabolism Physiology Plant Physiology
東京薬科大学_120305.indd
履 修 要 項 1 教 育 制 度 2 教 育 課 程 3 単 位 基 準 4 卒 必 要 単 位 数 5 卒 認 定 総 合 科 専 門 科 学 科 別 専 門 科 合 必 修 科 選 択 科 合 年 次 別 学 科 別 授 科 単 位 配 分 表 必 修 科 区 分 授 科 学 年 次 単 位 数 年 年 年 年 年 年 区 分 授 科 学 年 次 単 位 数 年 年 年 年 年 年 必 修 科
橡NO005-PDF用.ec5
(Biotechnology, Cell Biology, Genetics, Immunology, Medicine, Neuroscience, Structural Biology) (Cancer, Genetics, Immunology, Molecular Cell Biology, Neuroscience) InfoPort TEL: 043-290-2262 FAX:
JR東日本会社要覧2012-2013
Technology Planning Department Frontier Service Development Laboratory Advanced Railway System Development Center Safety Research Laboratory Disaster Prevention Research Laboratory Technical Center Environmental
98-02.PDF
1 982 2207 CAS 67630 2- H 3 C H 3 C CH OH C 3 H 8 O 60.10 1 99.9 % n- 1. 2-88.5 3 82.5 3 11.7c.c. 455 4 212 d 20 4 0.78505 3 2.1 = 1 4 4.4 kpa 33 mmhg20 4 log Pow0.05 0.07 5 m/z45, 1.0 43 0.19 27 0.17
Principles of Agricultural Sciences MOT Advanced Applied Biological Sciences Advanced Bioenvironmental Conservation Advanced Crop Production Advanced Life and Food Science Advanced Agricultural Economics
Special IssueDiagnoses and therapeutic agents for age-related diseases Reviews Original Case reports β Medicinal drugs affecting on clinical laboratory blood test results and adverse effects of them
History I COE
2008 108-8641 5-9-1 TEL 03-5791-6334FAX 03-5791-6335 [email protected] 228-8555 1-15-1 TEL 042-778-9760FAX 042-778-9761 [email protected] URL http://www.kitasato-u.ac.jp/lisci/index.html
1 911 9001030 9:00 A B C D E F G H I J K L M 1A0900 1B0900 1C0900 1D0900 1E0900 1F0900 1G0900 1H0900 1I0900 1J0900 1K0900 1L0900 1M0900 9:15 1A0915 1B0915 1C0915 1D0915 1E0915 1F0915 1G0915 1H0915 1I0915
Microsoft Word - web.docx
12 10 E 16:30 17:30 : ( ) " " ( ) 12 10 15:50 16:20 A 1 ( ) ( ) B ( ) ( ) D ( ) ( 12 11 B 10:00 12:00 " " ( ) ( ) 2 (10 ) A 1 ( ) 8:30 12:40 8:30 9:20 1 ( ) 1A-01 Cannabidiol-2',6'-dimethyl ether ( 1,
untitled
CONTENTS 01 02-03 04-05 06-07 09 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 48-49 50-51 52 01 02 Mishima,Michiaki 03 04 05 06 07 09 10 11
Microsoft Word - Ｈ22年度雄勝中央病院卒後臨床研修プログラム.docx
3 2 380 32 1 202,812 11,967 17.2 1,441 129 24 1 6 1 3 1 2 3 50-60 /2 2 2 1-2 2 1 2 2 1 1-2 1 CPC / 4 / / 2 / AED ICLS JPTEC 3 a: b: c: d: 4 c,d a b d 70% 2 10 4 11 12 21 7 21 8 5 Evidence Based Medicine
- 2 -
- 2 - - 3 - (1) (2) (3) (1) - 4 - ~ - 5 - (2) - 6 - (1) (1) - 7 - - 8 - (i) (ii) (iii) (ii) (iii) (ii) 10 - 9 - (3) - 10 - (3) - 11 - - 12 - (1) - 13 - - 14 - (2) - 15 - - 16 - (3) - 17 - - 18 - (4) -
2 1980 8 4 4 4 4 4 3 4 2 4 4 2 4 6 0 0 6 4 2 4 1 2 2 1 4 4 4 2 3 3 3 4 3 4 4 4 4 2 5 5 2 4 4 4 0 3 3 0 9 10 10 9 1 1
1 1979 6 24 3 4 4 4 4 3 4 4 2 3 4 4 6 0 0 6 2 4 4 4 3 0 0 3 3 3 4 3 2 4 3? 4 3 4 3 4 4 4 4 3 3 4 4 4 4 2 1 1 2 15 4 4 15 0 1 2 1980 8 4 4 4 4 4 3 4 2 4 4 2 4 6 0 0 6 4 2 4 1 2 2 1 4 4 4 2 3 3 3 4 3 4 4
1 (1) (2)
1 2 (1) (2) (3) 3-78 - 1 (1) (2) - 79 - i) ii) iii) (3) (4) (5) (6) - 80 - (7) (8) (9) (10) 2 (1) (2) (3) (4) i) - 81 - ii) (a) (b) 3 (1) (2) - 82 - - 83 - - 84 - - 85 - - 86 - (1) (2) (3) (4) (5) (6)
untitled
2009518 9:109:20 A 9:2010:20 O-01 9:209:30 RNAODN CREST O-02 9:309:40 CREST O-03 9:409:50 NO O-04 9:5010:00 -- O-05 10:0010:10 闐闐 ERATO O-06 10:1010:20 DNA B 10:2011:20 O-07 10:2010:30 O-08 10:3010:40
第６１巻５・６号（１２月号）／特集１頁目（本刷）
Special Issue 1Sudden cardiac death symposium in Tokushima Special Issue 2How to do for your health? Reviews Original Epidemiologic problems of sudden death of school children in Tokushima Prefecture
再生医科学研究所年報 Annual Report of the Institute for Frontier Medical Sciences Kyoto University Institute for Frontier Medical Sciences 1 2 3 4 5 6 Institute for Frontier Medical Sciences 1 Annual Report 2011
履 歴 書
,,,,,, Carboplatin and Monthly Paclitaxel Carboplatin and Weekly Paclitaxel 8(1), 25-34 (2006) Masayoshi KOINUMA, Takahisa YAMANASHI, Miwako KAMEI, Makoto SHIRAGAMI, The realities and Medical Expense of
県立大学薬学研究科2016四校.indd
1 Naoto Oku, Ph.D. Dean, Graduate Division of Pharmaceutical Sciences 2 3 Graduate Division of Pharmaceutical Sciences, University of Shizuoka Graduate Program in Pharmacy Pharmacy Practice & Science Graduate
< F83582E C0B2D929>
Welfare Society Public Involvement 231 General Theory of Social Welfare Statistics 232 Ethics Ethics 233 Modern Society and Public Quality General Theory of Law 234 General Theory of Law (Include International
30 (Electrical Engineering I) () LED IC 1. LED, IC D () 2 2 LED 6 4 ANDORNOTEXOR : : () () () () () 1 LED, IC 2 LED, IC LED, I
30 (Information Processing I) () 2 1 2 Word Excel WordExcel 1. EXCEL,WORD 2. D () 2 10 4 2 10 2 30 : () () () () () 1 EXCEL,WORD EXCEL,WORD EXCEL,WORD EXCEL,WORD 2 30 (Electrical Engineering I) () 2 1
Vol. 36, Special Issue, S 3 S 18 (2015) PK Phase I Introduction to Pharmacokinetic Analysis Focus on Phase I Study 1 2 Kazuro Ikawa 1 and Jun Tanaka 2
Vol. 36, Special Issue, S 3 S 18 (2015) PK Phase I Introduction to Pharmacokinetic Analysis Focus on Phase I Study 1 2 Kazuro Ikawa 1 and Jun Tanaka 2 1 2 1 Department of Clinical Pharmacotherapy, Hiroshima
1937 100 Q&A Q A 6 6 Q&A Q A EBM Q &A Q A 1 100 1 0 Q A WHO 1978 6000 1 2 17. 106 109, 2005., 1998 Q&A Q A C 1986 2 Narrative Based Medicine NBM NBM Q A Q: A 38 AT MD DO DO 1890 DD 2002 2007 3 2007
GCP 1) CSDDTufts Center for the Study of Drug Development 1980 2) 1980 6 1990 GCP 1997 GCP 198090 GCP 1990 2002 35 2000 3) 1) No.7 2002 2) Tufts Center for the Study of Drug DevelopmentOUTLOOK 20012002
,977 t 157,977 t mg l mg l BOD 9398 % OH = cm 3 / sec 11 = cm 3 / sec OH = /
1 9625 2219 CAS 75569 1, 2-1, 2- H 2 C CH CH 3 C 3 H 6 O 58.08 1 99 % 1. 2 2, 3-112.13 2, 3 34.23-37 449 2.8-37 % 2 d 0 4 0.859 4 d 20 0.8304 2 2, 4 2.00 = 1 53.33 kpa 400 mmhg18 59.33 kpa 445 mmhg20 5
研修コーナー
l l l l l l l l l l l α α β l µ l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l
30 II (Japanese II) ( ) ( ) B ( ) I III : ( ) : ( ) : ( ) ( ) ( ) ( ) ( ) ( )
II (Japanese II) () () 2 2 2 1. 2. 3. 4. B () 6 8 8 6 6 10 6 10 60 60 30 10 I III : (): (): () () () () () () 1 2 3 4 II (Geography History II) () () 2 2 2 1. 2. 3. 4. C () 1. 2 10 12 10 10 10 1989 1991
01-全体表紙.PDF
1 2005 11 26 1 1 5 15 18 1 1. 2005 11 26 09 00 1245 12 45 18207 2. 1,000 2,000 3. 4,000 2,000 5,000 4. 10,000 2,000 30,000 5. 1 20 10 1300 17 00 1500 1700 6. 7. TEL 047-372-4111 821 FAX 047-373-9901 [email protected]
04-p45-67cs5.indd
Journal of Sport and Exercise Psychology Motivation in sport and exercise. Journal of Sport and Exercise Psychology Journal of Applied Sport Psychology Psychological Review International Journal of Behavioral
_0212_68<5A66><4EBA><79D1>_<6821><4E86><FF08><30C8><30F3><30DC><306A><3057><FF09>.pdf
A. B. C. D. E. GIO SBO, MR Medical representative CRO contract research organization,,, HIV MR MR MR MR MR CRO contract research organization CRA CRO CRA I IV, CBT OSCE CBT computer based testing OSCE
第１章 製薬産業を取り巻く環境変化
2015 2007 5 1 2 2015 2007 5 103-0023 3-4-1 5F TEL : 03-5200-2681 FAX : 03-5200-2684 E-mail : [email protected] URL : http://www.jpma.or.jp/opir/ 3 4 5 6 1 2 3 4 1 2 3 4 5 6 7 8 9 10 11 2013 2014
4 15:10-15:50 ips 13 15:50-16:15 in vitro 14 16:15-16: :40-17: :05-17: :30-17:55 10, (), ( ), () *1A02 (),,, *1A03 FRET (), (),
(*Outstanding Poster Presentation ) 1F 12 14 1 10:30-10:55 2 10:55-11:20 3 11:20-11:45 1 11:45-12:25 MEMS 2 15:10-15:50 UT-Heart 4 15:50-16:15 5 16:15-16:40 6 16:40-17:05 7 17:05-17:30 RNA ips 8 17:30-17:55
H28.4 / 11 28 7 1 28 28 1 27 29 30 4 1 29 5 5 2 2 1 2 2 28 3 1 28 http://www.city.saitama.jp/005/001/018/003/p036471.html 2 28 7 11 28 8 31 3 CD DVD 4 4 5 7 11 8 31 9 1 9 30 10 1 10 31 11 1 11
08医療情報学22_1_水流final.PDF
22 (1), 702002: 59 59- The Problem of Nursing Common Language for the Information Sharing in Clinical Practice The fact-finding in regard to the correspondence between name and content of nursing action
KYOWA 07_eco_PDF.p
27 27 13 7 38 19 35 9 11 43 27 P4 276NPO 3BIOKYOWA P4 BIOKYOWA 2761 26 2626427 32626112 27 http://www.kyowa.co.jp/csr/sustain/index.html.....................................................................................
NL10
Information September, 2006 1 2 Japanese Association for Molecular Target Therapy of Cancer News Letter No.10 September, 2006 3 2006 4 Japanese Association for Molecular Target Therapy of Cancer News Letter
ッ ー ー ー() () 2.5 () () 21 1) -1 2) -2 10 m 5 7 23 6 1)2) 3) -1-2 H23.4.25 -15-20 4 75 5 1) -1 (5) (3) (3) (2) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) 1) ( 23 6 8 ) 2) 22 3)
PREFACE This report contains data on degrees awarded at Jackson State University by academic discipline, educational level and gender for the years. A
FIFTEEN REPORT OF DEGREES CONFERRED BY ACADEMIC DISCIPLINES PREFACE This report contains data on degrees awarded at Jackson State University by academic discipline, educational level and gender for the
